US 12,214,085 B2
Nanoparticles for preventing peri/post-menopausal bone loss and/or obesity
Sheba M. J. MohanKumar, Athens, GA (US); Puliyur S. MohanKumar, Athens, GA (US); and Yen-Jun Chuang, Athens, GA (US)
Assigned to UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., Athens, GA (US)
Filed by University of Georgia Research Foundation, Inc., Athens, GA (US)
Filed on Jun. 8, 2022, as Appl. No. 17/835,684.
Claims priority of provisional application 63/208,390, filed on Jun. 8, 2021.
Prior Publication US 2022/0387334 A1, Dec. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/51 (2006.01); A61K 38/47 (2006.01)
CPC A61K 9/5123 (2013.01) [A61K 38/47 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A pharmaceutical formulation for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject comprising
(a) a plurality of nanoparticles, wherein the nanoparticles comprise
a cage,
a surface modifying agent,
a targeting ligand, and
an active agent,
wherein the cage is a zeolitic imidazolate framework (“ZIF”)
wherein the surface modifying agent is attached to an outer surface of the cage and wherein the targeting ligand is exposed to a surrounding environment,
wherein the targeting ligand is a gonadotropin-releasing hormone (“GnRH”) receptor agonist, or a follicle stimulating hormone (“FSH”) receptor agonist, or a luteinizing hormone (“LH”) receptor agonist, or a combination thereof, and
wherein the active agent is encapsulated in the cage; and
(b) a pharmaceutically acceptable carrier and/or excipient.